ROLE OF HEPATITIS C VIRUS IN HEPATOCELLULAR CARCINOMA

确定丙型肝炎病毒（HCV）和B型肝炎病毒在 (HBV)在希腊肝细胞癌（HCC）的病因学中，血液 样本和问卷调查数据来自65例 HCC以及来自两组对照组的病例， 1991-1992年16个月期间的性别、年龄和医院。 HBsAg 在61.5%的HCC病例中检测到， 转移性肝癌和6.2%的其他对照;抗HCV 三组血清学阳性率分别为15.4%、4.6%和0。 Logistic回归模型比较HCC病例的优势比 与联合对照组相比，HBsAg的存在为19.2， 10.1抗HCV反应性。 为了确定HCV在10例肝癌死亡中的可能作用， 宫崎，日本，进行了巢式病例对照研究。 五 每个HCC病例的对照组按性别、年龄、 筛选和人T细胞嗜淋巴细胞病毒-I（HTLV-I）状态。 八十 10例患者中有10%和50例对照组中有38%的患者有任何血清学标志物， HCV感染;分别有70%和16%的患者有抗HCV。 9个肝脏 在接受测试的癌症病例中，44%的HCV-RNA阳性，而所有癌症病例中的32% 对照 仅1例病例和1例对照组HBsAg阳性。 比值比 (OR)估计HCV感染的任何标志物与 肝癌死亡率为6.2，与抗-HCV相关性更强 (OR=无穷大，p<0.001）。 HTLV-I 血清阳性率与HCV感染相关（OR = 1.6）;然而， 抗-HCV与肝癌死亡的相关性不因HTLV-I而异 status. 因此，抗HCV抗体与HCV感染者的死亡密切相关。 该人群中的肝癌。 HTLV-I的伴随存在 感染似乎没有显著改变这种关系， 尽管研究样本很小。

To determine the role of hepatitis C virus (HCV) and hepatitis B virus (HBV) in the etiology of hepatocellular carcinoma (HCC) in Greece, blood samples and questionnaire data were obtained from 65 incident cases of HCC as well as from two groups of controls matched to the cases on gender, age, and hospital during a 16-month period in 1991-1992. HBsAg was detected in 61.5% of HCC cases, 12.3% of control patients with metastatic liver cancer and 6.2% of the other controls; anti-HCV seropositivity was 15.4%, 4.6%, and 0 in the three groups, respectively. The odds ratios in logistic regression modelling comparing the HCC cases to the combined control series were 19.2 for the presence of HBsAg and 10.1 for anti-HCV reactivity. To determine the possible role of HCV in 10 liver cancer deaths in Miyazaki, Japan, a nested case control study was performed. Five controls for each HCC case were matched by gender, age, date of screening, and human T-cell lymphotropic virus-I (HTLV-I) status. Eighty percent of 10 cases and 38% of 50 controls had any serologic marker of HCV infection; 70% and 16%, respectively, had anti-HCV. Of 9 liver cancer cases tested, 44% were positive for HCV-RNA compared to 32% of all controls. Only 1 case and 1 control were HBsAg-positive. The odds ratio (OR) estimate for the association between any marker of HCV infection and liver cancer death was 6.2; the relationship with anti-HCV was stronger (OR = infinite, p<0.001) than with HCV-RNA (OR = 2.1). HTLV-I seroprevalence was correlated with HCV infection (OR = 1.6); however, the association of anti-HCV with liver cancer death did not vary by HTLV-I status. Thus, antibody to HCV was strongly associated with death from liver cancer in this population. The concomitant presence of HTLV-I infection did not appear to alter the relationship significantly, although the study sample was small.